The FDA placed the hold after researchers recorded a “higher than anticipated” incidence of deaths in a study testing “I-DXd” ...
Analysts said the deal makes sense for BioMarin, as it offers a late-stage clinical asset as well as two marketed therapies ...
The Belgian biotech is still on the hunt for partners after reporting that its drug succeeded against an inflammatory skin ...
Novo Nordisk's application for CagriSema comes at the same time as competitor Eli Lilly's ask for its obesity drug orforglipron. Elsewhere, Merck & Co. and Pfizer succeeded in a bladder cancer study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results